#1 Clinical Trials Search in Europe

Nimotuzumab

Nimotuzumab is an innovative monoclonal antibody that targets the epidermal growth factor receptor (EGFR). This article explores its use in clinical trials for treating various types of cancer, including pancreatic, nasopharyngeal, gastric, lung, and head and neck cancers. These trials aim to evaluate the drug’s effectiveness and safety, often in combination with other treatments such as chemotherapy and radiotherapy.

Table of Contents

What is Nimotuzumab?

Nimotuzumab is a type of medication known as a monoclonal antibody. It is specifically designed to target and block a protein called the epidermal growth factor receptor (EGFR), which is often found in high amounts on the surface of cancer cells. Nimotuzumab is also known by other names such as hR3, Theraloc, OSAG101, and Taixinsheng[1][8].

How Does Nimotuzumab Work?

Nimotuzumab works by attaching itself to the EGFR on cancer cells. This attachment blocks the signals that would normally tell the cancer cells to grow and divide. By interfering with these signals, nimotuzumab can help slow down or stop the growth of tumors[1].

Cancers Treated with Nimotuzumab

Nimotuzumab has been studied in the treatment of various types of cancer, including:

  • Pancreatic cancer: Both advanced or metastatic pancreatic cancer and pancreatic neuroendocrine neoplasms (a rare type of pancreatic cancer)[1][3]
  • Esophageal cancer: Locally advanced cases[2]
  • Nasopharyngeal carcinoma: Cancer that starts in the upper part of the throat behind the nose, especially recurrent cases[4]
  • Gastric cancer: Inoperable or recurrent stomach cancer[5]
  • Lung cancer: Particularly in cases where cancer has spread to the protective layers of the brain and spinal cord (leptomeningeal metastases)[6]
  • Head and neck squamous cell carcinoma: A type of cancer that begins in the flat cells that line the inside of the mouth, nose, and throat[7]

Administration and Dosage

Nimotuzumab is typically given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. The usual dose is 200 mg per week, although this can vary depending on the specific cancer being treated and other factors. The duration of treatment can range from 6 to 26 weeks or more, depending on the patient’s response and the treatment plan[2][7].

Combination Therapies

Nimotuzumab is often used in combination with other cancer treatments to potentially enhance its effectiveness. Some common combinations include:

  • Nimotuzumab with chemotherapy drugs like gemcitabine, cisplatin, or fluorouracil[1][2]
  • Nimotuzumab with radiation therapy[4]
  • Nimotuzumab with other targeted therapies like EGFR-TKIs (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors)[6]
  • Nimotuzumab with immunotherapy drugs like toripalimab[10]

Potential Side Effects

While nimotuzumab is generally considered to have a favorable safety profile compared to some other cancer treatments, it can still cause side effects. These may include:

  • Allergic reactions
  • Diarrhea
  • Vomiting
  • Skin reactions

It’s important to note that the severity and frequency of side effects can vary depending on the individual and the specific treatment regimen. Patients should always discuss potential side effects with their healthcare provider[6].

Ongoing Research

Nimotuzumab is still being studied in various clinical trials to better understand its effectiveness and safety in different types of cancer and treatment combinations. Some areas of ongoing research include:

  • Its use in combination with other immunotherapy drugs[10]
  • Its effectiveness in treating recurrent or metastatic cancers[10]
  • Its potential benefits when combined with standard treatments like chemotherapy and radiation therapy[7]

These studies aim to provide more information about how nimotuzumab can be best used to help cancer patients in the future.

Aspect Details
Drug Name Nimotuzumab
Drug Type Humanized monoclonal antibody targeting EGFR
Cancer Types Studied Pancreatic neuroendocrine neoplasms, nasopharyngeal carcinoma, gastric cancer, lung cancer, head and neck squamous cell carcinoma, esophageal carcinoma, EGFR-amplified solid tumors
Common Dosage 200mg or 400mg per week, administered intravenously
Combination Therapies Radiotherapy, chemotherapy (e.g., capecitabine, cisplatin), EGFR-TKIs
Primary Outcomes Measured Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), safety assessments
Secondary Outcomes Disease control rate, quality of life, specific survival rates
Safety Considerations Adverse events monitored and graded according to standardized criteria (e.g., CTCAE)

FAQ

  • What is Nimotuzumab? Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It's being studied in clinical trials for its potential to treat various types of cancer.
  • What types of cancer are being studied with Nimotuzumab? Clinical trials are exploring Nimotuzumab's effectiveness in several cancer types, including pancreatic neuroendocrine neoplasms, nasopharyngeal carcinoma, gastric cancer, lung cancer with leptomeningeal metastases, head and neck squamous cell carcinoma, esophageal carcinoma, and other EGFR-amplified solid tumors.
  • How is Nimotuzumab typically administered in these trials? In most trials, Nimotuzumab is administered intravenously, often at a dose of 200mg or 400mg per week. The duration and frequency of treatment can vary depending on the specific trial and cancer type being studied.
  • What are some common combinations being tested with Nimotuzumab? Nimotuzumab is being tested in combination with various treatments, including radiotherapy, chemotherapy drugs like capecitabine and cisplatin, and other targeted therapies such as EGFR-TKIs (tyrosine kinase inhibitors).
  • What are the main outcomes being measured in these clinical trials? The primary outcomes often include progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety assessments. Secondary outcomes may include disease control rate, quality of life measures, and specific survival rates for certain time periods.

Ongoing Clinical Trials on Nimotuzumab

  • Study on Radiotherapy with Nimotuzumab and Vinorelbine for Newly Diagnosed Childhood and Adolescent Diffuse Intrinsic Pontine Glioma (DIPG) Patients

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • EGFR: Epidermal Growth Factor Receptor, a protein on the surface of cells that plays a role in cell growth and division. It's often overexpressed in cancer cells and is a target for some cancer treatments.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. They can be used to detect or treat cancer.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment for a disease that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Disease Control Rate (DCR): The percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response, and stable disease to a therapeutic intervention in clinical trials.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Leptomeningeal Metastases: A condition where cancer cells spread to the membranes (meninges) surrounding the brain and spinal cord.
  • Tyrosine Kinase Inhibitors (TKIs): A type of targeted therapy that blocks specific enzymes called tyrosine kinases, which are involved in cancer cell growth and survival.

References

  1. https://clinicaltrials.gov/study/NCT00561990
  2. https://clinicaltrials.gov/study/NCT01249352
  3. https://clinicaltrials.gov/study/NCT05316480
  4. https://clinicaltrials.gov/study/NCT03666221
  5. https://clinicaltrials.gov/study/NCT01180166
  6. https://clinicaltrials.gov/study/NCT04833205
  7. https://clinicaltrials.gov/study/NCT05024019
  8. https://clinicaltrials.gov/study/NCT06363084
  9. https://clinicaltrials.gov/study/NCT02034968
  10. https://clinicaltrials.gov/study/NCT06509009